"10.1371_journal.pone.0067753","plos one","2013-07-04T00:00:00Z","Anita van Zwieten; Johanna Meyer; Daniel F Hermens; Ian B Hickie; David J Hawes; Nicholas Glozier; Sharon L Naismith; Elizabeth M Scott; Rico S C Lee; Adam J Guastella","Brain & Mind Research Institute, University of Sydney, Sydney, NSW, Australia; College of Medicine, University of Florida, Gainesville, Florida, United States of America","Conceived and designed the experiments: AJG AVZ JM DJH. Performed the experiments: DFH RSCL IBH EMS. Analyzed the data: AVZ NG AJG JM. Contributed reagents/materials/analysis tools: SLN DFH RSCL DJH. Wrote the paper: AVZ JM AJG. Read first draft of manuscript and edited, approved final manuscript: AVZ JM DFH IBH DJH NG SLN EMS RSCL AJG.","DFH is currently supported by a grant from the NSW Ministry of Health, Mental Health and Drug & Alcohol Office as well as an NHMRC Australia Fellowship (awarded to IBH). In 2007, he received honoraria for educational seminars from Janssen-Cilag. EMS is the (unpaid) Clinical Director of Headspace Services at the BMRI, the (unpaid) Co-ordinator of the Youth Mental Health Research Program at the BMRI and Deputy Director of St Vincent’s Private Hospital Young Adult Mental Health Unit. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli-Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. IBH is a member of the Medical Advisory Panel for BUPA Health Insurance (Australia) and also a Board Member of Psychosis Australia Trust. From 2012, he is a Commissioner in Australia’s new National Mental Health Commission. He was until January 2012 a director of headspace: the national youth mental health foundation. IBH was previously the chief executive officer (till 2003) and clinical adviser (till 2006) of beyondblue, an Australian National Depression Initiative. He is supported principally for clinical research in depression and health services and population health initiatives related to anxiety and depression by an NHMRC Australian Medical Research Fellowship (2007–2012). He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of nongovernment organisations and the pharmaceutical industry (including Pfizer, Servier and Astra Zeneca). He has served on advisory boards convened by the pharmaceutical industry in relation to specific antidepressants, including nefazodone, duloxetine and desvenlafaxine. He leads a new investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier but also by other NHMRC funding) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. In addition to national and international government-based grant bodies, investigator-initiated mental health research at the BMRI, he has been supported by various pharmaceutical manufacturers (including Servier and Pfizer) and not-for-profit entities (including the Heart Foundation, beyondblue and the BUPA Foundation). None of these declared interests alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","07","Anita van Zwieten","AVZ",10,TRUE,4,4,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
